Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biotech Acquisition Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) G1125A124** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. ** Reflects the CUSIP number for the Issuers Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant (the Units). The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.G1125A124 1 Names of Reporting Persons Atalaya Capital Management LP 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 6,875 7 Sole Dispositive Power 0 8 Shared Dispositive Power 6,875 9 Aggregate Amount Beneficially Owned by Each Reporting Person 6,875 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) Less than 0.1% 12 Type of Reporting Person (See Instructions) IA, PN CUSIP No.G1125A124 1 Names of Reporting Persons Atalaya Special Purpose Investment Fund LP 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 6,875 7 Sole Dispositive Power 0 8 Shared Dispositive Power 6,875 9 Aggregate Amount Beneficially Owned by Each Reporting Person 6,875 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) Less than 0.1% 12 Type of Reporting Person (See Instructions) PN CUSIP No.G1125A124 1 Names of Reporting Persons Corbin ERISA Opportunity Fund, Ltd. 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 618,750 7 Sole Dispositive Power 0 8 Shared Dispositive Power 618,750 9 Aggregate Amount Beneficially Owned by Each Reporting Person 618,750 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) 2.7% 12 Type of Reporting Person (See Instructions) OO CUSIP No.G1125A124 1 Names of Reporting Persons Corbin Capital Partners GP, LLC 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 928,125 7 Sole Dispositive Power 0 8 Shared Dispositive Power 928,125 9 Aggregate Amount Beneficially Owned by Each Reporting Person 928,125 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) 4.0% 12 Type of Reporting Person (See Instructions) OO CUSIP No.G1125A124 1 Names of Reporting Persons Corbin Capital Partners, L.P. 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 928,125 7 Sole Dispositive Power 0 8 Shared Dispositive Power 928,125 9 Aggregate Amount Beneficially Owned by Each Reporting Person 928,125 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) 4.0% 12 Type of Reporting Person (See Instructions) IA, PN CUSIP No.G1125A124 1 Names of Reporting Persons Corbin Opportunity Fund, L.P. 2 Check the appropriate box if a member of a Group (see instructions) (a) [x] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 309,375 7 Sole Dispositive Power 0 8 Shared Dispositive Power 309,375 9 Aggregate Amount Beneficially Owned by Each Reporting Person 309,375 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [] 11 Percent of class represented by amount in row (9) 1.3% 12 Type of Reporting Person (See Instructions) PN

Explanatory Note This Amendment No. 2 (the Amendment) amends, in its entirety, the Amendment No. 1 to the Statement on Schedule 13G filed by the reporting persons therein on December 14, 2021, which, due to an administrative error, misattributed the shares held of record by Atalaya Special Purpose Investment Fund LP to Atalaya Capital Management LP. In addition, as described below, this Amendment is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the Common Stock. Item 1(a). Name of Issuer: Biotech Acquisition Company Item 1(b). Address of Issuers Principal Executive Offices: 545 West 25th Street, 20th Floor, New York, NY 10001 Item 2(a). Name of Person Filing: This Statement is filed on behalf of the following persons (collectively, the Reporting Persons): i. Atalaya Capital Management LP (ACM); ii. Atalaya Special Purpose Investment Fund LP (ASPIF); iii. Corbin ERISA Opportunity Fund, Ltd. (CEOF); iv. Corbin Capital Partners GP, LLC (Corbin GP); v. Corbin Capital Partners, L.P. (CCP); and vi. Corbin Opportunity Fund, L.P. (COF). Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of ACM and ASPIF is One Rockefeller Plaza, 32nd Floor, New York, NY 10020. The address of the principal business office of each of CEOF, Corbin GP, CCP, and COF is 590 Madison Avenue, 31st Floor, New York, NY 10022. Item 2(c). Citizenship: Each of ACM, ASPIF, CCP and COF is a Delaware limited partnership. CEOF is a Cayman Islands exempted company. Corbin GP is a Delaware limited liability company. Item 2(d). Title and Class of Securities: Class A common stock, par value $0.0001 per share (the Shares) Item 2(e). CUSIP Number: G1125A124 Item 3. If This Statement is Filed Pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a: This Item 3 is not applicable. Item 4(a). Amount Beneficially Owned: As of the date hereof, ACM may be deemed the beneficial owner of 6,875 Shares underlying Units, which amount includes 6,875 Shares underlying Units held of record by ASPIF. Each of Corbin GP and CCP may be deemed the beneficial owner of 928,125 Shares underlying Units, which amount includes (i) 618,750 Shares underlying Units held of record by CEOF and (ii) 309,375 Shares underlying Units held of record by COF. In addition to the securities reported on the cover pages hereto, ACM may be deemed to beneficially own 278,437 warrants underlying Units held of record by ASPIF. Each of Corbin GP and CCP may be deemed to beneficially own (i) 309,375 warrants underlying Units held of record by CEOF and (ii) 154,687 warrants underlying Units held of record by COF. Each warrant will become exercisable on the later of (i) 30 days after the completion of a business combination and (ii) 12 months after the closing of the Issuers initial public offering. The warrants will expire on the fifth anniversary of the completion of a business combination. Item 4(b). Percent of Class: As of the date hereof, ACM may be deemed the beneficial owner of less than 0.1% of Shares outstanding, which amount includes less than 0.1% of Shares outstanding held of record by ASPIF. Each of Corbin GP and CCP may be deemed the beneficial owner of approximately 4.0% of Shares outstanding, which amount includes (i) 2.7% of Shares outstanding held of record by CEOF and (ii) 1.3% of Shares outstanding held of record by COF. These percentages are based on 23,000,000 Shares outstanding as reported in the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 17, 2021. The percentages reported in the cover pages and this Item 4(b) herein do not include any Shares underlying warrants since the warrants are not exercisable within sixty days. Item 4(c). Number of shares as to which such person has: ACM: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 6,875 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 6,875 ASPIF: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 6,875 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 6,875 CEOF: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 618,750 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 618,750 Corbin GP: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 928,125 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 928,125 CCP: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 928,125 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 928,125 COF: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 309,375 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 309,375 The Shares are directly held by ASPIF, CEOF and COF (the Direct Holders). As ASPIFs investment manager, ACM has the power to vote and direct the disposition of all Shares held by ASPIF. As CEOF and COFs investment manager, CCP has the power to vote and direct the disposition of all Shares held by CEOF and COF. This report shall not be deemed an admission that ACM, CCP, Corbin GP, the Direct Holders or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Act, or for any other purpose. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [x]. Item 6. Ownership of more than Five Percent on Behalf of Another Person. This Item 6 is not applicable. Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. This Item 7 is not applicable. Item 8. Identification and classification of members of the group. ACM, ASPIF, CEOF, Corbin GP, CCP, and COF may be deemed members of a group, as defined in Rule 13d-5 under the Act, with respect to the Shares. Such group may be deemed to beneficially own 935,000 Shares. CEOF, Corbin GP and CCP disclaim beneficial ownership over the Shares held directly by ASPIF. Item 9. Notice of Dissolution of Group. This Item 9 is not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 2022 Atalaya Capital Management LP By: /s/ Drew Phillips Name: Drew Phillips Title: Authorized Signatory Atalaya Special Purpose Investment Fund LP By: Atalaya Capital Management LP, its investment manager By: /s/ Drew Phillips Name: Drew Phillips Title: Authorized Signatory Corbin ERISA Opportunity Fund, Ltd. By: Corbin Capital Partners, L.P., its Investment Manager By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel Corbin Capital Partners GP, LLC By:/s/ Daniel Friedman Name: Daniel Friedman Title: Authorized Signatory Corbin Capital Partners, L.P. By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel Corbin Opportunity Fund, L.P. By: Corbin Capital Partners, L.P., its Investment Manager By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). EXHIBIT INDEX Ex. No. Description 99 Joint Filing Agreement JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 2 to the statement on Schedule 13G with respect to shares of Class A Common Stock of Biotech Acquisition Company is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 14, 2022 Atalaya Capital Management LP By: /s/ Drew Phillips Name: Drew Phillips Title: Authorized Signatory Atalaya Special Purpose Investment Fund LP By: Atalaya Capital Management LP, its investment manager By: /s/ Drew Phillips Name: Drew Phillips Title: Authorized Signatory Corbin ERISA Opportunity Fund, Ltd. By: Corbin Capital Partners, L.P., its Investment Manager By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel Corbin Capital Partners GP, LLC By:/s/ Daniel Friedman Name: Daniel Friedman Title: Authorized Signatory Corbin Capital Partners, L.P. By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel Corbin Opportunity Fund, L.P. By: Corbin Capital Partners, L.P., its Investment Manager By:/s/ Daniel Friedman Name: Daniel Friedman Title: General Counsel